Herbalife
Herbalife's revenue rose 0.9% to $5.0 billion in fiscal 2025. Its operating margin was 9.6%, up from 7.7% a year earlier. Free cash flow was $253 million, up 54.8%. It paid out $8 million in dividends and buybacks, 3% of free cash flow. The diluted share count rose 2.0%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on capital is after-tax operating income as a share of the money invested in the business: debt plus equity, minus cash. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
What Herbalife does
Herbalife sells nutrition products: weight management items such as meal replacement shakes and teas, targeted nutrition supplements, energy and sports products, and skin and hair care. At December 31, 2025 it sold 144 product types in 95 markets. It does not sell mainly through stores. It uses direct selling: a network of independent Members, some who buy for their own use and some who resell or build their own sales organizations.
Weight management is its largest category, followed by targeted nutrition. Its best-selling line, Formula 1 Nutritional Shake Mix, approximated 25% of net sales.
The company gives Members coaching and support, and says its Members provide personalized support to their customers. It is subject to a Consent Order with the FTC and to extensive rules covering its products and network marketing program.
Its biggest risks, as it describes them
- Failing to keep its Members and sales leaders, who sell its products and are not employees.
- Members' conduct and bad publicity about the company or direct selling.
- One product line, Formula 1, makes up a significant part of net sales.
- Rules on network marketing and its Consent Order with the FTC.
- A large part of its business is outside the U.S., including in China, with its own legal and economic risks.
Income statement
From fiscal 2016 to 2025, earnings per share grew 4.3% a year and net income fell 1.4% a year, as buybacks cut the share count by 40%.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 602 | 508 | 575 | 415 | 353 |
| Debt incl. finance leases | 2,764 | 2,693 | 2,564 | 2,262 | 1,995 |
| Net debt (negative means net cash) | 2,162 | 2,185 | 1,989 | 1,847 | 1,642 |
| Net debt to EBITDA | 2.6x | 3.3x | 4.2x | 3.6x | 2.7x |
| Debt to equity | — | — | — | — | — |
| Interest coverage | 4.8x | 3.9x | 2.1x | 1.8x | 2.2x |
| Current ratio | 1.3x | 1.4x | 1.1x | 0.9x | 1.1x |
| Quick ratio | 0.8x | 0.8x | 0.7x | 0.5x | 0.6x |
Cash flow
Projections
Project Herbalife's revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
Insider trades
Over the 12 months between November 14, 2025 and November 13, 2026, 2 insiders bought $181,510 of Herbalife shares on the open market, and 2 insiders sold $2.6 million.
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Jun 4, 2026 | Sophie L'HeliasDirector | Bought | 1,200 | $11.31 | $13,572 | Form 4 |
| May 19, 2026 | Troy HicksChief Operating Officer | Sold | 10,000 | $12.32 | $123,200 | Form 4 |
| May 18, 2026 | Troy HicksChief Operating Officer | Sold | 38,377 | $12.93 | $496,215 | Form 4 |
| May 12, 2026 | Frank LambertiChief Commercial Officer | Sold | 134,982 | $13.50 | $1.8 million | Form 4 |
| May 11, 2026 | Frank LambertiChief Commercial Officer | Sold | 7,937 | $13.86 | $110,007 | Form 4 |
| Dec 1, 2025 | Sophie L'HeliasDirector | Bought | 800 | $12.70 | $10,160 | Form 4 |
| Nov 26, 2025 | Sophie L'HeliasDirector | Bought | 400 | $13.22 | $5,288 | Form 4 |
| Nov 18, 2025 | Lynda CloudDirector | Bought | 17,000 | $8.97 | $152,490 | Form 4 |
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | 5 of 9 | 6 of 9 | 6 of 9 |
| Rule of 40 | 1.7% | 1.9% | 5.9% |
| Altman Z'' | −0.38 | −0.46 | 0.63 |
| Accruals ratio | −7.8% | −1.1% | −3.8% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Pass | Pass | Pass |
| Cash from operations is positive | Pass | Pass | Pass |
| Return on assets rose | Fail | Pass | Fail |
| Cash from operations exceeds net income | Pass | Pass | Pass |
| Debt fell relative to assets | Pass | Pass | Pass |
| Current ratio rose | Fail | Fail | Pass |
| Share count didn't rise | Fail | Fail | Fail |
| Gross margin rose | Fail | Pass | Fail |
| Revenue rose relative to assets | Pass | Fail | Pass |
| F-score | 5 of 9 | 6 of 9 | 6 of 9 |
Compare
Put Herbalife side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| Herbalife | FY25 | 0.9% | 9.6% | 5.0% | 36.6% | 2.7x | 6 | |
| Coty | FY26 | −1.5% | −1.4% | 6.0% | −0.9% | 7.3x | 3 | Compare |
| Haleon | FY25 | −1.8% | 21.9% | 21.0% | 7.9% | 2.6x | 7 | Compare |
| Estée Lauder Companies | FY26 | 5.0% | 5.2% | 8.7% | 4.9% | 2.4x | 6 | Compare |
| e.l.f. Beauty | FY26 | 24.6% | 4.5% | 11.6% | 3.8% | 3.6x | 4 | Compare |
10 years of figures
| Fiscal year | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | 4,488 | 4,428 | 4,892 | 4,877 | 5,542 | 5,803 | 5,204 | 5,062 | 4,993 | 5,038 |
| Revenue growth | 0.4% | −1.4% | 10.5% | −0.3% | 13.6% | 4.7% | −10.3% | −2.7% | −1.4% | 0.9% |
| Gross profit | 3,634 | 3,579 | 3,972 | 3,919 | 4,391 | 4,564 | 4,031 | 3,871 | 3,889 | 3,923 |
| Research and development | — | — | — | — | — | — | — | — | — | — |
| Operating income | 458 | 617 | 683 | 568 | 641 | 734 | 545 | 356 | 386 | 481 |
| Net income | 260 | 214 | 297 | 311 | 373 | 447 | 321 | 142 | 254 | 228 |
| Diluted EPS (US$) | 1.51 | 1.29 | 1.98 | 2.20 | 2.77 | 4.13 | 3.23 | 1.42 | 2.50 | 2.20 |
| Diluted shares (millions) | 172 | 166 | 150 | 142 | 134 | 108 | 100 | 100 | 102 | 104 |
| Cash flow | ||||||||||
| Cash from operations | 367 | 591 | 648 | 458 | 629 | 460 | 352 | 358 | 285 | 333 |
| Capital expenditure | 143 | 96 | 84 | 106 | 112 | 151 | 156 | 135 | 122 | 80 |
| Free cash flow | 224 | 495 | 564 | 351 | 517 | 309 | 196 | 222 | 163 | 253 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 13 | 844 | 750 | 17 | 924 | 1,011 | 147 | 11 | 8 | 8 |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 26 |
| Stock-based compensation | 40 | 42 | 36 | 39 | 51 | 54 | 44 | 48 | 50 | 44 |
| Balance sheet at fiscal year end | ||||||||||
| Cash and short-term investments | 844 | 1,279 | 1,199 | 839 | 1,045 | 602 | 508 | 575 | 415 | 353 |
| Debt incl. finance leases | 1,448 | 2,268 | 2,454 | 1,804 | 2,429 | 2,764 | 2,693 | 2,564 | 2,262 | 1,995 |
| Total assets | 2,565 | 2,895 | 2,790 | 2,679 | 3,076 | 2,820 | 2,732 | 2,809 | 2,728 | 2,786 |
| Total liabilities | 2,369 | 3,230 | 3,513 | 3,069 | 3,932 | 4,211 | 3,998 | 3,870 | 3,529 | 3,295 |
| Shareholders' equity | 196 | −335 | −723 | −390 | −856 | −1,392 | −1,266 | −1,060 | −801 | −515 |
| Margins and ratios | ||||||||||
| Gross margin | 81.0% | 80.8% | 81.2% | 80.4% | 79.2% | 78.6% | 77.5% | 76.5% | 77.9% | 77.9% |
| Operating margin | 10.2% | 13.9% | 14.0% | 11.7% | 11.6% | 12.7% | 10.5% | 7.0% | 7.7% | 9.6% |
| Net margin | 5.8% | 4.8% | 6.1% | 6.4% | 6.7% | 7.7% | 6.2% | 2.8% | 5.1% | 4.5% |
| Free cash flow margin | 5.0% | 11.2% | 11.5% | 7.2% | 9.3% | 5.3% | 3.8% | 4.4% | 3.3% | 5.0% |
| Rule of 40 (growth + FCF margin) | 5.4% | 9.8% | 22.0% | 6.9% | 22.9% | 10.0% | −6.5% | 1.7% | 1.9% | 5.9% |
| Return on capital | 44.2% | 42.4% | 73.6% | 70.8% | 83.9% | 90.2% | 48.8% | 27.0% | 39.1% | 36.6% |
| Return on equity | — | — | — | — | — | — | — | — | — | — |
| Return on assets | 10.3% | 7.8% | 10.4% | 11.4% | 12.9% | 15.2% | 11.6% | 5.1% | 9.2% | 8.3% |
| Net debt to EBITDA | 1.1x | 1.4x | 1.6x | 1.4x | 1.9x | 2.6x | 3.3x | 4.2x | 3.6x | 2.7x |